MREA Clinical trials

Marea Therapeutics Enrolls First Patient in Phase 2b TYDAL-TIMI 78 Clinical Study Evaluating MAR001 in Adults at Risk of ASCVD

Published August 04, 2025 at 12:00 PM

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that the first patient has been enrolled in Marea’s Phase 2b TYDAL-TIMI 78 study evaluating MAR001 in adults with elevated levels of triglycerides (TG) and remnant cholesterol (RC) at increased risk of atherosclerotic cardiovascular disease

Related Questions

What are the specific inclusion and exclusion criteria for patients in this study, and could they impact enrollment speed? What is the projected impact of the Phase 2b trial on Marea’s cash runway and future financing needs? When is the anticipated timeline for full enrollment in the TYDAL‑TIMI 78 Phase 2b study? Are there any disclosed or anticipated partnerships or licensing agreements related to MAR001 that could affect valuation? How might the results of TYDAL‑TIMI 78 position MAR001 for advancement into a Phase 3 program, and what timelines are expected for that transition? How does MAR001’s mechanism of action differ from existing triglyceride‑lowering therapies such as EPA/DHA formulations or PCSK9 inhibitors? What safety signals have emerged in Phase 1 or early Phase 2 data, and how might they influence investor sentiment? How does the Phase 2b design (dose, endpoints, patient population) compare to competitor programs in the same therapeutic area? When can we expect the first interim efficacy and safety data readout from the TYDAL‑TIMI 78 trial? What size does Marea anticipate the commercial market for a TG/RC‑lowering therapy to be, and what market share could be realistic if MAR001 succeeds? What are the primary efficacy endpoints (e.g., % reduction in TG, RC, or CV events) and are they considered clinically meaningful by the market? What potential regulatory pathway (e.g., FDA accelerated approval, cardiovascular outcome trial) does Marea anticipate for MAR001 if Phase 2b data are positive?